Skip to content

A single-center, investigator-blinded, randomized controlled clinical study to evaluate the effect of maintenance therapy with Cetaphil Moisturising Cream on the improvement of clinical symptoms of mild to moderate atopic dermatitis in infancy and the preventive effect on disease relapse during maintenance period

A single-center, investigator-blinded, randomized controlled clinical study to evaluate the effect of maintenance therapy with Cetaphil Moisturising Cream on the improvement of clinical symptoms of mild to moderate atopic dermatitis in infancy and the preventive effect on disease relapse during maintenance period

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100055060
Enrollment
Unknown
Registered
2021-12-31
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis (AD)

Interventions

Experimental group:Cetaphil Moisturizing Cream + Cetaphil Skin Restoring Daily Body Wash
Control group:Cetaphil Skin Restoring Daily Body Wash

Sponsors

Beijing Children's Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 2 Years

Inclusion criteria

Inclusion criteria: 1. Meet the Hanifin and Rajka diagnostic criteria for atopic dermatitis; 2. Aged >28 days and <=2 years, no gender limit; 3. Within one week of successful topical glucocorticoid treatment, mild to moderate atopic dermatitis has been controlled (IGA is 0 or 1); 4. The subject's guardian agrees to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. The subject has a bacterial, viral, fungal or parasitic skin infection; 2. Those who are allergic to Cetaphil moisturizing moisturizing cleanser or Cetaphil moisturizing cream; 3. Subject has ulcerative lesions, acne or rosacea; 4. Those who have systematically used glucocorticoids, immunomodulators or immunosuppressants (except antihistamines) within 4 weeks before the screening evaluation; 5. Those who have participated in other clinical trials within 3 months before the screening evaluation; 6. Other conditions that the investigator considers unsuitable to participate in clinical research.

Design outcomes

Primary

MeasureTime frame
Time to relapse;

Secondary

MeasureTime frame
Relapse rate of AD;Subject's IGA score;Subject's EASI score;Physician's subjective evaluation of moisturizing;Subjective evaluation of moisturizing by patients (guardians);

Countries

China

Contacts

Public ContactMa Lin

Beijing Children's Hospital, Capital Medical University

bch_maleen2021@126.com+86 10 59616882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026